Hero Finding
The same identity content read completely differently by market: top-2 appeal at first exposure ranged from 59% in China to 13% in Japan.
At the blinded first exposure, respondents saw the identity content with no brand attached. Japan's read was structurally different rather than lukewarm: 36% of Japanese respondents, and 48% of Japanese patients, rated the content not at all appealing, against 2% in China. A blended global average would have reported a comfortable middle and hidden exactly the market where the identity needed work.
Top-2 appeal at blinded first exposure · share rating the content very or extremely appealing · N=1,511
Key Findings
What the four-market read surfaced.
Five signals shaped the identity decision and the launch sequencing behind it, each grounded in per-market, stat-tested cuts of the same instrument.
The same content read completely differently by market, and a blended average would have hidden it.
Top-2 appeal at the blinded first exposure ran 59% in China, 38% in Germany, 33% in the United States and 13% in Japan, a fivefold spread on identical stimuli. Japan's pattern was structural: 36% of Japanese respondents, and 48% of Japanese patients, rated the content not at all appealing, against 2% in China. Per-market reporting, not a blended global number, is what made the divergence visible.
Deeper exposure moved every market; the rank order barely changed.
After the fuller branded presentation, top-2 appeal rose from 36% to 54% overall, with the United States climbing from 33% to 59%, Germany from 38% to 60%, China from 59% to 71% and Japan from 13% to 24%. Outright rejection halved from 15% to 7%. The identity earns preference when it has room to explain itself, so first-touch formats carry more risk than full-story formats.
The forced-choice comparison gave the decision meeting one consistent answer.
Identity A won 54% to 46% overall and led in all four countries: 59% in Japan, 56% in Germany, 53% in the United States and 52% in China. Physicians were more decisive than patients, 61% of the 500-physician sample against a near-even 51% among patients, and respondents highly familiar with the company's existing brand also leaned A. The direction held everywhere the data was cut, across 40+ stat-tested segment columns, the kind of result a leadership team can act on without relitigating segments.
Adaptive probing attached reasoning to the exact words the design team cared about.
The AI moderator monitored each respondent's own descriptive adjectives and, whenever an on-strategy word appeared, modern, bold, innovative or creative in any of the four languages, probed why in that respondent's language. The instrument captured 93,000+ respondent messages, roughly 62 per interview, at a 24-minute median length, with full verbatim capture across all 32 quota cells.
The compression protected the client's analysis window rather than consuming it.
All 32 audience, country and specialty quota cells held simultaneously across three recruiting networks, including a 200-physician cell in the United States and 100-physician cells in Germany, China and Japan, inside roughly 90 hours in field. The reconciled respondent-level dataset reached the commissioning firm's analysts a week before their final meeting with the end client's brand leadership.
Shown with no brand attached, the new identity read nearly as strongly technology as healthcare.
Going in, the open question was whether a deliberately modern identity still reads as healthcare at all. The blinded category-attribution test put numbers on it: 45% of respondents placed the unbranded content in healthcare and 31% in pharmaceuticals, while 40% read it as a technology company and 12% could not classify it at all. Among physicians the healthcare read strengthened to 50%. The branded follow-up showed the brand name closes most of that gap: 60% said the content did a very or extremely good job representing a modern, bold and innovative healthcare company, rising to 79% in China. The distance between the blinded read and the branded read is the quantified cost, and the calculated bet, of a deliberately modern identity.
I can see that they take a professional approach while standing by their patients and showing determination to create change for the future.
Patient · Japan
Study Design
N=1,511
4 markets
4 languages
500 physicians
1,011 patients
The commissioning firm brought its own questionnaire. UserCue programmed it natively in English, German, Mandarin and Japanese and held 32 audience, country and specialty quota cells live at once across three recruiting networks, roughly 90 hours in field, with screener terminations and QC removals excluded before the 1,511 base was locked.
Sample by segment
Mix
What the guide covered
- Blinded first exposure to the identity content, with impression measures taken before any brand reveal
- Deeper branded exposure with matched impression scales, isolating what fuller context earns
- 23-attribute brand descriptor battery, fielded in three parts
- Blinded category attribution: what type of company the unbranded content could represent
- Forced-choice comparison of the two candidate identities against the company's mission statement
- Benchmark against the current in-market identities of four global pharmaceutical peers
- AI-probed open ends on first impressions and on-strategy descriptor choices
Who qualified
- Practicing physicians clearing specialty, tenure and clinical-time screens across six specialty groups
- Diagnosed patients carrying a qualifying diagnosis
- Fielded under industry-standard pharmaceutical research compliance, including adverse-event reporting consent
- Quota-controlled across 32 concurrent audience, country and specialty cells
Crosstab · Exposure by Market
Every market lifted with fuller context; the rank order barely changed.
Share rating the identity content very or extremely appealing at the blinded first exposure and after the deeper branded exposure. Highlighted row = the most receptive market at both exposures.
| First exposure · top-2 | Deeper exposure · top-2 | |
|---|---|---|
| China | 59% | 71% |
| Germany | 38% | 60% |
| United States | 33% | 59% |
| Japan | 13% | 24% |
| All markets | 36% | 54% |
N=1,511 · four markets · both audiences · China most receptive and Japan least, at both exposures · Outright rejection halved: 15% to 7% · Stat-tested across 40+ segment columns
Voice of the Field
What physicians and patients actually said.
Verbatims from the AI-moderated interviews, captured natively in each market's language and selected across all four markets and both audiences.
“To be honest, I feel there's too much information and it comes across as cluttered and disorganized. I find it difficult to understand what the main message is trying to convey.”
“Well, I understand what the company is trying to do, but I'm not into over-the-top, emotionally charged advertising content. I would much prefer clear statements about the product, with figures on effectiveness and compatibility.”
“I think this could be a promotion for a sports apparel brand, or it could be a promotion for medical apparel - both are about making breakthroughs possible.”
“I was unsure what particular product was being messaged.”
“More positive. It gives more clarity about what it's about. It creates a socially oriented impression.”
“I thought the content I watched was very modern because of the people that were in it and what they were doing. It's something new, not something I'd seen before, and that's the reason I really didn't understand what it was talking about.”
Implications · what the evidence supports
Three readings from the research.
What the commissioning firm's analysts carried into the end-client decision meeting, grounded in per-market, stat-tested cuts.
The launch question is sequencing and format depth by market, not a single global go or no-go.
China stayed the most receptive market and Japan the least, at both exposures. Japan is where the identity needs the most explanatory room: 13% top-2 appeal at first exposure and 48% of Japanese patients rating the content not at all appealing. A blended global average would have reported a comfortable middle and hidden exactly that.
First-touch formats carry more risk than full-story formats.
Every market lifted with fuller context: the United States from 33% to 59%, Germany from 38% to 60%, China from 59% to 71% and Japan from 13% to 24%, with outright rejection halving from 15% to 7%. The identity earns preference when it has room to explain itself, and the format mix determines how often it gets that room.
Identity A is the version the evidence backs in every cut.
Identity A won the forced choice 54% to 46% overall, led in all four countries and took 61% of the 500-physician sample against a near-even 51% among patients. Respondents highly familiar with the company's existing brand also leaned A. The direction was consistent across 40+ stat-tested segment columns, which removes the need to relitigate segments after the decision.
Signals the data flagged
- Japan is the outlier market: 13% top-2 appeal at first exposure and 48% of Japanese patients rating the content not at all appealing
- Physicians separate the identities hardest: 61% choose identity A against a near-even 51% among patients
- Deeper exposure halves outright rejection from 15% to 7% and lifts top-2 appeal in every market
- 12% of respondents could not classify the unbranded identity at all
Risks the data surfaced
| First-touch formats land before the identity can explain itself | High |
| Japan reads the identity structurally differently from the other markets | High |
| Unbranded, the identity reads nearly as technology as healthcare | Med |
| Blended global reporting hides the per-market divergence | Med |